Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow PODD
Insulet Corporation (PODD) Operating cash flow
Insulet Corporation's operating cash flow for fiscal 2025 was $569.3M, up 32.3% from $430.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was $511.2M. Over the past ten years it has ranged from −$68.1M (fiscal 2021) to $569.3M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 4 consecutive fiscal years. Insulet Corporation ranks 14th of 149 Medical Devices companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $569.3M | 32.33% |
| FY2024 | $430.2M | 195.26% |
| FY2023 | $145.7M | 22.44% |
| FY2022 | $119.0M | — |
| FY2021 | −$68.1M | — |
| FY2020 | $84.0M | (14.63%) |
| FY2019 | $98.4M | 174.09% |
| FY2018 | $35.9M | (13.08%) |
| FY2017 | $41.3M | 159.57% |
| FY2016 | $15.9M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $88.4M | (22.32%) |
| Mar 2026 | $113.8M | (37.92%) |
| Dec 2025 | $183.3M | 45.82% |
| Sep 2025 | $125.7M | (36.03%) |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $3.1B |
| GMED Globus Medical, Inc. compare | $910.4M |
| PODD Insulet Corporation | $511.2M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $492.6M |
| BIO Bio-Rad Laboratories, Inc. compare | $492.6M |
| HAE Haemonetics Corporation compare | $328.1M |
| PEN Penumbra, Inc. compare | $277.8M |
| BRKR Bruker Corporation compare | $190.4M |
| GKOS Glaukos Corporation compare | −$950.0K |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on PODD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement